We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Paysafe
PSFE
$351M
| $11.5K | ﹤0.01% |
911
-45,939
| -98% | -$628K |
|
1802
SM Energy
SM
$8.76B
| $11.4K | ﹤0.01% |
461
-298,463
| -100% | -$7.23M |
|
1803
Cullinan Oncology
CGEM
$1.45B
| $11.3K | ﹤0.01% |
1,495
-963
| -39% | -$7.74K |
|
1804
Telephone and Data Systems
TDS
$3.82B
| $11.2K | ﹤0.01% |
316
-207
| -40% | -$7.26K |
|
1805
Acadia Pharmaceuticals
ACAD
$5.12B
| $11.2K | ﹤0.01% |
519
-1,798
| -78% | -$33.4K |
|
1806
Jasper Therapeutics
JSPR
$23.3M
| $11K | ﹤0.01% |
1,977
+920
| +87% | +$4.53K |
|
1807
OraSure Technologies
OSUR
$254M
| $10.7K | ﹤0.01% |
3,569
| – | – |
|
1808
Dorman Products
DORM
$3.8B
| $10.7K | ﹤0.01% |
87
-33
| -28% | -$4.01K |
|
1809
Intrepid Potash
IPI
$507M
| $10.6K | ﹤0.01% |
298
+178
| +148% | +$6.07K |
|
1810
Worthington Steel
WS
$1.75B
| $10.5K | ﹤0.01% |
353
-1,249
| -78% | -$32.2K |
|
|
CIO
1811
DELISTED
City Office REIT
CIO
| $10.4K | ﹤0.01% |
1,953
| – | – |
|
|
AVDL
1812
DELISTED
Avadel Pharmaceuticals
AVDL
| $10.4K | ﹤0.01% |
+1,175
| New | +$10.3K |
|
1813
Central Garden & Pet Co Class A
CENTA
$2.36B
| $10.2K | ﹤0.01% |
325
+14
| +5% | +$437 |
|
1814
Diamondback Energy
FANG
$56.1B
| $10.2K | ﹤0.01% |
74
-82
| -53% | -$11.4K |
|
|
CTLP
1815
DELISTED
Cantaloupe
CTLP
| $10.1K | ﹤0.01% |
922
-289,762
| -100% | -$2.51M |
|
1816
Caribou Biosciences
CRBU
$178M
| $9.97K | ﹤0.01% |
7,917
-5,614
| -41% | -$5.52K |
|
1817
Willdan Group
WLDN
$1.34B
| $9.75K | ﹤0.01% |
+156
| New | +$7.44K |
|
1818
World Acceptance Corp
WRLD
$886M
| $9.74K | ﹤0.01% |
59
-19
| -24% | -$2.71K |
|
1819
Kontoor Brands
KTB
$4.18B
| $9.7K | ﹤0.01% |
147
-140
| -49% | -$9.05K |
|
1820
FuboTV Inc
FUBO
$305M
| $9.6K | ﹤0.01% |
+207
| New | +$7.75K |
|
1821
Carter Bankshares
CARE
$742M
| $9.52K | ﹤0.01% |
549
+303
| +123% | +$4.79K |
|
1822
Vaalco Energy
EGY
$607M
| $9.5K | ﹤0.01% |
+2,631
| New | +$9.14K |
|
1823
BJ's Restaurants
BJRI
$1.36B
| $9.41K | ﹤0.01% |
+211
| New | +$8.33K |
|
|
BCPC
1824
Balchem Corp
BCPC
$5.67B
| $9.39K | ﹤0.01% |
59
-25
| -30% | -$4.05K |
|
1825
Conduent
CNDT
$271M
| $9.31K | ﹤0.01% |
3,527
| – | – |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.